US tax reform: Implications for pharma and life sciences

In December 2017, the United States enacted the most comprehensive tax reform in more than 30 years. For the pharmaceutical and life sciences sector, the changes will impact both US and non-US headquartered companies doing business in the United States. PwC hosted a webinar on 15 May 2018 to examine the main provisions of the reform.

In this recorded presentation, PwC specialists take a deeper dive into US tax reform to review some of the new rules, questions that companies are asking and reactions from other governments. View the recording to hear more about the 2017 tax reform reconciliation act, and what tax professionals need to think about.